

1 **TABLE S1** Baseline characteristics of ASPECT-NP participants by population^a

Characteristic	Statistic or group	EEA population dataset (N = 231)	ITT population (N = 362)
Age, yrs	Mean (SD)	60.0 (16.4)	60.5 (16.7)
	Median (min–max)	62.0 (18–98)	62.5 (18–98)
Age group, <i>n</i> (%)	<65 yrs	131 (56.7)	202 (55.8)
	≥65 yrs	100 (43.3)	160 (44.2)
	<75 yrs	184 (79.7)	279 (77.1)
	≥75 yrs	47 (20.3)	83 (22.9)
Body weight, kg	Mean (SD)	81.2 (16.6)	80.9 (17.3) ^c
	Median (min–max)	80.0 (42.0–146.0)	80.0 (34.0–150.1) ^c
CrCl, mL/min ^b	Mean (SD)	108.5 (60.0)	105.0 (59.3) ^d
	Median (min–max)	97.1 (16.0–427.9)	95.0 (16.0–427.9) ^d
CrCl category, <i>n</i> (%) ^b	≥150 mL/min (ARC)	46 (19.9)	67 (18.5)
	≥80 to <150 mL/min (normal)	109 (47.2)	160 (44.2)
	>50 to <80 mL/min (mild impairment)	46 (19.9)	82 (22.7)

Characteristic	Statistic or group	EEA population	ITT population
		dataset (<i>N</i> = 231)	(<i>N</i> = 362)
	≥30 to ≤50 mL/min (moderate)	19 (8.2)	35 (9.7)
	≥15 to <30 mL/min (severe impairment)	11 (4.8)	17 (4.7)
APACHE II score	Mean (SD)	17.4 (5.1)	17.5 (5.2) ^d
	Median (min–max)	17.0 (2.0–32.0)	17.0 (2.0–33.0) ^d
SOFA score	Mean (SD)	6.3 (2.3)	—
	Median (min–max)	6.0 (0.0–15.0)	—
CPIS	Mean (SD)	9.9 (1.8)	—
	Median (min–max)	10.0 (5.0–13.0)	—
CPIS, <i>n</i> (%)	≤6	14 (6.1)	25 (6.9)
	7	17 (7.4)	29 (8.0)
	8	17 (7.4)	45 (12.4)
	>8	183 (79.2)	263 (72.7)
Sex, <i>n</i> (%)	Male	174 (75.3)	262 (72.4)
	Female	57 (24.7)	100 (27.6)

Characteristic	Statistic or group	EEA population dataset (N = 231)	ITT population (N = 362)
Race, <i>n</i> (%)	Asian	18 (7.8)	27 (7.5)
	Black or African American	6 (2.6)	10 (2.8)
	White	194 (84.0)	301 (83.1)
	Native Hawaiian/Pacific Islander	1 (0.4)	1 (0.3)
	Other/not reported	12 (5.2)	23 (6.4)
Region, <i>n</i> (%)	North America	8 (3.5)	15 (4.1)
	Latin America	13 (5.6)	21 (5.8)
	Western Europe	35 (15.2)	53 (14.6)
	Eastern Europe	147 (63.6)	231 (63.8)
	Asia/Pacific	18 (7.8)	28 (7.7)
	Rest of world	10 (4.3)	14 (3.9)
Prior antibacterial therapy failure for VNP, <i>n</i> (%)	Yes	34 (14.7)	53 (14.6)
VABP diagnosis, <i>n</i> (%)	Yes	182 (78.8)	263 (72.7)

Characteristic	Statistic or group	EEA population dataset (N = 231)	ITT population (N = 362)
Diabetes, <i>n</i> (%)	Yes	51 (22.1)	88 (24.3)
Congestive heart failure, <i>n</i> (%)	Yes	37 (16.0)	55 (15.2)
Chronic obstructive pulmonary disease, <i>n</i> (%)	Yes	15 (6.5)	40 (11.0)
Bacteremic, <i>n</i> (%)	Yes	37 (16.0)	25 (6.9)
Gram-negative adjunct therapy, <i>n</i> (%)	Yes	61 (26.4)	103 (28.5)
Gram-positive adjunct therapy, <i>n</i> (%)	Yes	224 (97.0)	350 (96.7)
PaO ₂ /FiO ₂ >240, <i>n</i> (%)	Yes	56 (24.2)	93 (25.7)
Empyema, <i>n</i> (%)	No	231 (100.0)	361 (99.7)
Pleural effusion, <i>n</i> (%)	No	215 (93.1)	323 (89.2)
Ventilation of ≥5 days, <i>n</i> (%)	Yes	125 (54.1)	182 (50.3)
Hospitalization of ≥5 days, <i>n</i> (%)	Yes	179 (77.5)	278 (76.8)

Characteristic	Statistic or group	EEA population	ITT population
		dataset (<i>N</i> = 231)	(<i>N</i> = 362)
Prior antibacterial use, <i>n</i> (%)	Yes	214 (92.6)	318 (87.8)
<i>Enterobacterales</i> , <i>n</i> (%)	Yes	170 (73.6)	195 (73.9) ^e
Polymicrobial LRT pathogen, <i>n</i> (%)	Yes	91 (39.4)	100 (37.9) ^e

2 ^aAPACHE, Acute Physiology and Chronic Health Evaluation; ARC, augmented renal clearance; CPIS, Clinical Pulmonary Infection
3 Score; CrCl, creatinine clearance; EEA, exposure–efficacy analysis; ITT, intention-to-treat; LRT, lower respiratory tract; PaO₂/FiOS,
4 ratio of partial pressure of oxygen to fractional inspired oxygen; SOFA, Sequential Organ Failure Assessment; VABP, ventilator-
5 associated bacterial pneumonia; VNP, ventilated nosocomial pneumonia.

6 ^bCalculated using central laboratory data.

7 ^c*N* = 359.

8 ^d*N* = 361.

9 ^e*N* = 264.

10

11 **TABLE S2** Summary of 28-day all-cause mortality and clinical cure at test of cure visit for ASPECT-NP participants by baseline
 12 creatinine clearance group.^{a,b}

13

Renal function subgroup	<u>28-day all-cause mortality, n/N (%)</u>		<u>Clinical cure at test of cure, n/N (%)</u>	
	Alive	Death	Cure	Failure
All	195/231 (84.4)	36/231 (15.6)	151/231 (65.4)	80/231 (34.6)
CrCl ≥15 to <30 mL/min	8/11 (72.7)	3/11 (27.3)	5/11 (45.5)	6/11 (54.5)
CrCl ≥30 to ≤50 mL/min	15/19 (78.9)	4/19 (21.1)	8/19 (42.1)	11/19 (57.9)
CrCl >50 mL/min	172/201 (85.6)	29/201 (14.4)	138/201 (68.7)	63/201 (31.3)

14 ^aCrCl, creatinine clearance.

15 ^bCalculated using central laboratory data.

16